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The relationship between anticipated response and subsequent experience of cancer 1 
treatment-related side effects: A meta-analysis comparing effects before and after treatment 2 
exposure 3 
 4 
Abstract  5 
Objective: To review the evidence for a systematic relationship between cancer patients’ pre-6 
treatment expectations (anticipated side effects) and subsequent experience of treatment-7 
related side effects, and to compare this relationship in patients with no prior treatment 8 
experience (cognitive expectations) and with some prior treatment experience (conditioned 9 
response). 10 
Methods: A total of 12,952 citations were identified through a comprehensive search of the 11 
literature published on or before November 2016 and screened against inclusion criteria. 12 
Studies were eligible if they included participants undergoing curative treatment for cancer, 13 
measured a treatment side effect, examined the relationship between anticipation and 14 
experience of side effects, and reported quantitative data.  15 
Results: Thirty-one studies were included in the review and meta-analysis (total N = 5,069). 16 
The side effects examined were nausea (anticipatory and post-treatment), vomiting, fatigue, 17 
pain, problems with concentration, and skin reactions. Meta-analyses indicated significant 18 
and positive associations between anticipation and subsequent experience for all included 19 
side effects in patients with no prior treatment exposure (r = 0.153 – 0.431). Stronger 20 
associations were found for all included conditioned side effects in patients with previous 21 
treatment experience (r = 0.211 – 0.476). No significant differences were found when overall 22 
effect sizes for patients with and without prior treatment exposure were compared for each 23 
side effect, except for anticipatory nausea (p = 0.012). 24 
3 
 
Conclusion: These results may have implications for future interventions that target patients’ 1 
expectations of cancer treatment-related side effects. Future research could explore patient 2 
reports of messages received about likely treatment effects both before and during treatment.  3 
  4 
Keywords: cancer, cancer treatment, conditioning, expectancies, expectancy, side effects  5 
  6 
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1. Introduction 1 
Cancer patients report experiencing a range of treatment-related side effects including 2 
pain, fatigue, nausea and vomiting, and even cognitive decline, although the nature and extent 3 
of these can vary between individuals undergoing the same treatment 
1
. Some side effects, 4 
such as nausea, may be more common depending on the type of chemotherapy that the 5 
patient receives. Other individual differences contribute to the experience of these side 6 
effects, above and beyond variations in the specific treatment provided. These effects have 7 
been variously described as expectancy, conditioning and nocebo effects with considerable 8 
overlap in theorising around each 
2, 3
. Response expectancies could be described as largely 9 
cognitive and reflect anticipation of subsequent experience prior to any treatment. In general, 10 
the side effects that a patient experiences are attributed to exposure to information about 11 
possible negative experiences of treatment. By contrast, it is possible to interpret some of the 12 
negative side effects of treatment as arising from conditioning. According to this 13 
interpretation, exposure to treatment (i.e., the unconditioned stimulus), which results in a 14 
negative experience (i.e., the unconditioned response), may become paired with contextual 15 
cues, such as attendance at the infusion suite (i.e., the conditioned stimulus), and result in a 16 
similar negative response (i.e., the conditioned response; nausea).This response may be 17 
experienced either before or after treatment but requires at least one trial that pairs treatment 18 
with side-effects.    19 
By contrast, nocebo effects (the negative equivalent to the placebo effect) have been 20 
described as being mediated by both expectations (i.e., response expectancies) and previous 21 
experience (i.e., conditioning). Stewart-Williams and Podd 
4
 suggest that although 22 
conditioning and direct information provision can each shape conscious expectations, 23 
classical conditioning without changed expectations (i.e., without conscious learning), can 24 
also produce negative outcomes.  25 
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One possible strategy for discriminating between a non-conditioned (“expected”) and 1 
a conditioned side effect is to note the incidence of the side effect before and after exposure 2 
to any treatment. “Side effects” generated before the patient has received any treatment (e.g., 3 
anticipatory nausea before attendance for first chemotherapy session) are likely due to 4 
expectations (also called “response expectancies”). Comparable side effects experienced after 5 
one or more treatment cycles may reflect learning via conditioning, or response expectancies, 6 
or both. The finding that “repeated exposure to chemotherapy increases risk for the 7 
development of Anticipatory Nausea and Vomiting (ANV) conforms to a classical 8 
conditioning model, wherein repeated pairings of unconditioned (i.e., chemotherapy) and 9 
conditioned stimuli (e.g., the clinic, the nurse) produce nausea and vomiting even before 10 
administration of emetogenic agents.” p. 173 5 This observation confirms the importance of 11 
identifying the stage of treatment at which side effects are first reported, and whether these 12 
change over the treatment course. 13 
A recent meta-analysis of cancer treatment side effects was undertaken by Sohl, 14 
Schnur and Montgomery 
6
. The study aimed to determine the size of the relationship between 15 
“expectations for non-volitional responses” (p. 775) (response expectancies) associated with 16 
cancer treatment and patients’ experiences of these side effects.  On the basis of 14 included 17 
studies, results confirmed a medium-sized association (r = 0.36) between response 18 
expectancies and experienced side effects.  Importantly, treatment exposure resulted in 19 
stronger associations supporting the potential importance of the contribution of classical 20 
conditioning.  21 
The current review aims to replicate and update the Sohl, Schnur and Montgomery 
6
 22 
paper in order to re-evaluate the evidence for a systematic relationship between cancer 23 
patients’ expectations, duration of exposure to treatment, and experience of cancer-treatment-24 
related side effects. The current review builds upon their analysis by comparing the 25 
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relationship between patients with no prior treatment experience (where the effect must raise 1 
from cognitive expectations) and those with some prior treatment experience (where the 2 
response may include a conditioned response) for each side effect. The treatment side effects 3 
included in the review replicate and extend those reported by Sohl, Schnur and Montgomery 4 
6
, and include nausea (anticipatory and post-treatment), post-treatment vomiting, fatigue, 5 
pain, skin reactions, and problems with concentration. It was hypothesised that associations 6 
between side effects and experience would be greater in patients with some treatment 7 
experience (conditioned side effects with and without a possible contribution from 8 
expectations) than in patients without prior treatment experience (response expectancy effects 9 
only; no conditioning).  10 
2. Methods 11 
 12 
2.1. Search strategy 13 
The first author (CF) conducted an extensive systematic search of the literature 14 
published up to and including November 2016 using MEDLINE, PubMed, SCOPUS, 15 
PsycINFO, Informit, Web of Science, and CINAHL databases. The following search string 16 
was used: (expectation OR expectations OR expectancy OR expectancies OR expect* OR 17 
anticipatory OR anticipations OR anticipat* OR somatic OR somatisation OR somati* OR 18 
nocebo) AND (“side effects” OR “adverse effects” OR “treatment side effects” OR outcomes 19 
OR “adverse outcomes” OR nausea OR emesis OR vomit* OR fatigue OR cognitive OR 20 
cognition OR memory OR attention OR concentration OR hair loss OR alopecia OR 21 
neuropathy OR anxiety OR depression OR survival OR morbidity OR mortality OR 22 
breathlessness OR dyspnoea OR libido OR appetite OR constipation OR diarrhoea OR pain) 23 
AND (radiotherapy OR chemotherapy OR surgery OR treatment) AND (cancer OR neoplasm 24 
OR oncology). Searches were limited to studies conducted with human participants and 25 
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published in English. Reference lists of extracted articles were manually searched for 1 
additional, potentially eligible studies that were not retrieved from the database searches.  2 
The initial search was conducted on the 26
th
 of July 2015. A total of 11,343 citations 3 
were identified through the search (11,339 from electronic database searches and four 4 
through manual searching of reference lists). Duplicate articles were removed (n = 2,868) and 5 
the first and fourth authors (CF and EG) independently reviewed the remaining 8,475 titles 6 
for relevant articles. There was almost perfect (99%) agreement between reviewers (Kappa = 7 
0.74, p < 0.001). Abstracts of potentially eligible articles (n = 225) were reviewed 8 
independently by the first and second authors (CF and CW). Reviewers agreed on 70% of 9 
decisions (Kappa = 0.33, p < 0.001) with final agreement negotiated, where required. The 10 
full-text of the remaining articles (n = 107) were obtained and screened against the inclusion 11 
criteria and a further 76 articles were excluded as they did not meet the eligibility criteria (see 12 
Figure 1 for the PRISMA flow diagram for reasons for exclusion). Any disagreements about 13 
inclusion were resolved through discussion among the research team.  14 
The remaining 31 articles met the inclusion criteria and were included in the meta-15 
analysis. This included one article that described two separate studies and another two articles 16 
describing the same study (these data were included only once). An updated search was 17 
conducted on the 23
rd
 of November 2016 to identify articles published since the initial search 18 
was conducted. An additional 1,609 citations were identified; however none of the studies 19 
met the inclusion criteria. The meta-analysis included all of the studies analysed by Sohl, 20 
Schnur and Montgomery 
6
, except for two studies that did not include a measure of 21 
anticipated response to treatment 
7, 8
 and an additional 14 studies identified in the literature 22 
search. 23 
2.2.Selection criteria 24 
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Studies were eligible for inclusion if they examined the relationship between patient 1 
anticipation of side effects and their subsequent occurrence, duration, frequency, or severity 2 
in patients undergoing cancer-related treatment. This included patients with no previous 3 
treatment experience (potential “cognitive expectations” effect) or with some previous 4 
treatment experience (potential “conditioned response”). The side effects included were 5 
nausea, vomiting, fatigue, pain, skin reactions, and problems with concentration. 6 
Eligible studies were required to meet the following criteria:  7 
1) included participants undergoing curative treatment for cancer; 8 
2) employed a measure of anticipated response to treatment; 9 
3) examined the relationship between anticipation and experience of cancer treatment-10 
related side effects; and 11 
4) reported quantitative data (either an effect size or enough statistical information to 12 
calculate an effect size). 13 
Studies were excluded during the screening process if; anticipation of treatment-14 
related side effects was not measured, the study was a review or meta-analysis of the 15 
literature, the associations between anticipated and experienced side effects were not 16 
reported, the sample was not cancer patients, the study focussed on mental health issues, or if 17 
treatment was palliative or involved complementary and alternative therapies (i.e., not 18 
adjuvant therapies used for curative purposes).  19 
2.3.Quality assessment  20 
The first and third authors (CF and AH) assessed the methodological quality of 21 
studies included in the meta-analysis using the Qualsyst tool 
9
, which was developed for 22 
assessment of the quality of both qualitative and quantitative studies that employ any study 23 
9 
 
design. The Qualsyst tool for assessment of the quality of quantitative studies is comprised of 1 
14 items that are scored as yes, partial, no or not applicable. Examples of the items are; is the 2 
question/objective sufficiently described, is the sample size appropriate, and have they 3 
controlled for confounding. A summary score was calculated for each paper and then a final 4 
score was calculated by dividing the summary score by the total possible score (determined 5 
by subtracting the Not Applicable responses). Mean quality score for each paper was 6 
calculated by averaging the scores given to each paper by the two assessors. These scores are 7 
documented in Supplementary Table 1 (range: 0.66 to 1.0). The scores assigned by the first 8 
assessor ranged from 0.59 to 1.0 (mean: 0.81, standard deviation: 0.09). The scores assigned 9 
by the second assessor ranged from 0.64 to 1.0 (mean: 0.85, standard deviation: 0.10). Both 10 
assessors assigned the same score to six studies (19%). Good inter-rater reliability was 11 
observed (r = 0.60). Discrepancies in the scores of the remaining studies ranged from 0.01 to 12 
0.18 and were resolved through discussion. Articles were not excluded from the meta-13 
analysis based on a threshold Qualsyst score.  14 
2.4.Data extraction 15 
The first author (CF) extracted key descriptive data and effect sizes for the 16 
relationship between anticipated response and subsequent experience of side effects. 17 
Descriptive data extracted related to the study design (e.g., cross-sectional, 18 
longitudinal/prospective, experimental), sample size, sample characteristics (e.g., gender, 19 
cancer type, treatment type), whether participants had previous experience of cancer 20 
treatment, instrument used to measure anticipation of treatment-related side effects, when 21 
anticipation of side effects was measured (e.g., before first treatment, before treatment other 22 
than the first, before multiple treatments), which side effects were experienced, and whether 23 
occurrence, duration, frequency, or severity (or combination) of side effects were assessed. 24 
Reported effect sizes or statistical information needed to compute effect sizes for the 25 
10 
 
relationship between anticipated response and subsequent experience of side effects were also 1 
extracted. 2 
2.5.Data analysis 3 
2.5.1. Effect size 4 
The effect size correlation coefficient (ESr) was used as the outcome in the meta-5 
analysis. Positive values indicated an association between anticipated response and 6 
subsequent experience of the side effect measured by indices including, duration, frequency, 7 
and severity. Effect sizes (Pearson’s r) were directly available in many of the studies 10-21. In 8 
cases where a correlation coefficient was not reported, mean side effects scores and standard 9 
deviations 
22
, t-tests 
23
, number of side effect events and non-events 
24
, chi-square statistics 
25-
10 
27
, odds ratios 
28-31
, change in R square 
23
, or Beta-coefficients 
32-39
 were used to estimate 11 
effect sizes utilizing formulas suggested in the literature 
40, 41
. 12 
Several studies reported results for multiple indices of side effects (e.g., nausea 13 
duration, nausea severity, and nausea unpleasantness) or multiple time-points (e.g., cycles of 14 
chemotherapy). In these cases, an average effect size was calculated for each separate side 15 
effect so that each study contributed only one effect size for each side effect to the meta-16 
analysis. 17 
2.5.2. Meta-analysis 18 
The meta-analysis was conducted using Comprehensive Meta-Analysis Software V3 19 
42
. Analyses were conducted separately for each side effect and for patients with and without 20 
prior treatment experience. Overall effect sizes were calculated when relevant data were 21 
available from at least three studies. Following recommendations by Borenstein and 22 
colleagues 
40
, a random-effects modelling approach was used to account for variation in 23 
11 
 
sampling in the included studies. Q tests were conducted to investigate differences in effect 1 
sizes in patients with no prior treatment experience versus some prior treatment experience. 2 
2.5.3. Heterogeneity 3 
The I
2 
statistic was calculated for each analysis to assess the consistency of the results 4 
of included studies. The I
2 
statistic describes the percentage of total variation between study 5 
results that is due to genuine underlying differences (heterogeneity) rather than chance 
43
. It is 6 
a measure of inconsistency of results. According to Higgins and colleagues 
43
, levels of 7 
heterogeneity can be described as low (I
2 
= 25%), moderate (I
2 
= 50%), and high (I
2 
= 75%), 8 
with a lower level indicating less inconsistency in results. 9 
2.5.4. Publication bias 10 
Publication bias was assessed using Rosenthal’s 44 Classic Fail-Safe N (Nfs), Orwin’s 11 
45
 Nfs, and Egger’s test 
46
. Rosenthal’s Nfs estimates the number of unpublished studies 12 
reporting null results that would be needed to increase the P-value for the meta-analysis to 13 
above 0.05. Orwin’s Nfs takes a more conservative approach to estimate the number of studies 14 
needed to reduce the effect size to a specified level other than zero (defined in the present 15 
meta-analysis as r ≤ 0.05). An effect size was considered to be robust if Rosenthal’s Nfs was 16 
larger than 5k + 10, where k is the number of studies included in the analysis. Rosenthal’s Nfs 17 
of less than the recommended criterion (5k + 10) indicated potential publication bias, which 18 
was further investigated using Egger’s test. Where Egger’s test confirmed a publication bias, 19 
an adjusted effect size was estimated using Duval and Tweedie’s 47 trim-and-fill method, 20 
which uses imputations of missing results to recalculate the effect size. 21 
3. Results 22 
3.1.Study Characteristics 23 
12 
 
The meta-analysis included the results of 31 studies with a total of 5,069 participants. 1 
Studies had an average sample size of 164 (ranging from 20 
16
 to 911 
29
). Fifteen of the 2 
studies included participants with breast cancer 
11, 13-17, 20, 22, 25, 26, 28, 30, 32, 35, 36
. Other cancers 3 
studied included ovarian 
23
 and mixed cancer types 
10, 12, 18, 19, 21, 23, 24, 29, 31, 33, 34, 37-39
. One 4 
study did not specify the types of cancer that participants were diagnosed with 
27
. The most 5 
commonly studied side effect was post-treatment nausea (77% 
10-12, 14, 15, 17, 19-25, 27, 29-31, 33-39
), 6 
followed by post-treatment vomiting (39% 
11, 17, 20, 23, 24, 27, 28, 31, 34, 36-38
), fatigue (29% 
11, 13-15, 
7 
20, 24, 33, 37, 38
), pain (23% 
11, 14-16, 24, 37, 38
), anticipatory nausea (16% 
12, 13, 26, 30, 32
), skin 8 
reactions (13% 
18, 24, 37, 38
), and problems with concentration (6% 
37, 38
).  9 
Study designs were predominantly prospective and longitudinal. Several studies were 10 
randomised controlled trials, comparing antiemetic regimens 
39
, or testing whether the 11 
assessment of patients’ expectations of side effects were related to their experience of side 12 
effects 
33
, the effectiveness of a pre-surgery hypnosis session in reducing post-surgery pain 
16
, 13 
and the effectiveness of educational or informational interventions to reduce post-treatment 14 
nausea 
19, 21
. Another study analysed data collected from participants in the control arm of a 15 
larger randomised controlled trial 
17
. Studies used a variety of instruments to measure 16 
patients’ anticipation of side effects, including the Side Effect Expectancy Questionnaire 10, 12, 17 
18, 19, 21-26, 30, 32
, the Symptom Experience and Expectation Interview Schedule 
27
, visual 18 
analogue scales 
11, 13-16, 20, 29, 31, 37, 38, 48
, and other Likert-type scales 
17, 33-36, 39
. The actual 19 
experience of side effects was assessed using the Morrow Assessment of Nausea and Emesis 20 
12, 30, 34, 36
, the Brief Pain Inventory 
15
, the Rhodes Index of Nausea and Vomiting 
27
, the 21 
MASCC Antiemesis Tool 
31
, patient report diaries 
17, 19-23, 28, 29, 39, 48
, symptom checklists 
32, 35
, 22 
visual analogue scales 
10, 11, 13, 14, 16, 18, 29, 33, 37, 38
, and other Likert-type scales 
13, 17, 19-21, 23-25, 48
. 23 
Most studies included participants undergoing chemotherapy (80% 
10-13, 17-20, 22-33, 35-
24 
39
). The remaining studies included participants undergoing surgery 
14-16
 and radiotherapy 
18, 
25 
13 
 
21
. Twenty-six of the studies measured anticipation of side effects prior to the first treatment, 1 
two studies measured anticipation prior to each of multiple cycles of treatment (one of which 2 
also measured anticipation prior to the first treatment), and the final three studies measured 3 
anticipation prior to any treatment session but not the first. Experience of the side effect was 4 
measured after the first treatment in 13 of the studies, after each of multiple treatment 5 
sessions in 13 of the studies, and any treatment other than the first in five studies.  6 
3.2. Association between anticipation and experience of side effects 7 
Analyses were conducted to investigate the overall effect of anticipation on each of 8 
the seven side effects: anticipatory nausea, post-treatment nausea, post-treatment vomiting, 9 
fatigue, pain, skin reactions, and problems with concentration (Table 1). Analyses were also 10 
conducted to investigate differences in effect sizes for each side effect in patients with and 11 
without previous treatment experience (Table 2). An insufficient number of studies meant 12 
that analyses could not be conducted for anticipatory nausea in patients with no prior 13 
treatment experience and for pain, problems with concentration, and skin reactions in patients 14 
with some previous treatment experience. 15 
3.2.1. Overall effect of anticipation on side effects 16 
Results indicated significant, medium, positive associations between anticipated 17 
effects of treatment and experience of anticipatory nausea (ESr = 0.442), fatigue (ESr = 18 
0.325), pain (ESr = 0.364), and problems with concentration (ESr = 0.431). Significant, 19 
small, positive associations were found between anticipation and experience of post-20 
treatment nausea (ESr = 0.230), vomiting (ESr = 0.181), and skin reactions (ESr = 0.290). 21 
Findings for anticipatory nausea, post-treatment nausea, vomiting, fatigue, pain, and 22 
problems with concentration appeared to be robust, with Rosenthal’s Nfs exceeding the 23 
recommended criterion, 5k + 10. This was not the case for the effect size for skin reactions, 24 
14 
 
where Rosenthal’s Nfs (N = 20) was less than the recommended criterion (N = 30). This 1 
indicated a potential publication bias, however this was not confirmed by Egger’s test (p = 2 
0.122). Only two studies investigated the relationship between anticipation and problems 3 
with concentration therefore the potential for publication bias could not be assessed. 4 
3.2.2. Effect of anticipation on side effects in patients with no prior treatment experience 5 
Significant associations were found between anticipation and experience of each of 6 
the side effects, with medium, positive associations for fatigue (ESr = 0.337), pain (ESr = 7 
0.366), and problems with concentration (ESr = 0.431) in patients with no previous treatment 8 
experience. Small, positive associations were found for post-treatment nausea (ESr = 0.200), 9 
post-treatment vomiting (ESr = 0.170), and skin reactions (ESr = 0.278). There was evidence 10 
of potential publication bias in the finding for post-treatment vomiting, with the 11 
recommended criterion (N = 45) exceeding Rosenthal’s Nfs (N = 42). Egger’s test supported 12 
the presence of a publication bias (p = 0.012). Therefore, imputations of missing results were 13 
used to calculate an adjusted effect size (ESr = 0.153), which was considerably smaller than 14 
the unadjusted effect for post-treatment vomiting. The recommended criterion (N = 25) also 15 
exceeded Rosenthal’s Nfs (N = 12) indicating potential publication bias in the finding for skin 16 
reactions, however this was not supported by Egger’s test (p = 0.220) and an adjusted effect 17 
size was not calculated. 18 
3.2.3. Effect of anticipation on side effects in patients with prior treatment experience 19 
Significant, medium, positive associations were found between anticipation and 20 
experience of anticipatory nausea (ESr = 0.476) and post-treatment nausea (ESr = 0.288) in 21 
patients who had some prior treatment experience. Significant, small, positive associations 22 
were also found for post-treatment vomiting (ESr = 0.211) and fatigue (ESr = 0.266). The 23 
effect size for pain was medium in size (ESr = 0.235), but was not significant. Overall effect 24 
15 
 
sizes could not be calculated for problems with concentration and skin reactions because 1 
there were not enough data to run the meta-analysis. Rosenthal’s Nfs (N = 13) was less than 2 
the recommended criterion (N = 35) for post-treatment vomiting, indicating a potential 3 
publication bias. Egger’s test was conducted, but did not provide evidence of a publication 4 
bias (p = 0.881). Rosenthal’s Nfs also indicated potential publication bias in the finding for 5 
fatigue, however this was not supported by Egger’s test (p = 0.933). 6 
3.2.4. Differences in effect in patients with and without prior treatment experience 7 
Contrary to the main hypothesis, no significant differences in effect sizes were found 8 
in patients with and without prior treatment experience for post-treatment nausea, post-9 
treatment vomiting, fatigue, pain, problems with concentration, and skin reactions (Table 4). 10 
The difference between effect sizes for the relationship between anticipation of side effects 11 
and the experience of anticipatory nausea in patients with and without prior treatment 12 
experience was significant (p = 0.012), with a greater effect size for patients with prior 13 
treatment experience (ESr = 0.476). However, only one study examined anticipation of side 14 
effects and the experience of anticipatory nausea in patients with no previous treatment 15 
experience with results indicating only a non-significant, small, positive association (r = 16 
0.036 
12
), so this result should be interpreted with caution. 17 
4. Discussion 18 
Results of the meta-analysis confirmed those of Sohl, Schnur and Montgomery 
6
; a 19 
medium effect size which varied with previous treatment experience. Our results extend these 20 
previous results by analysing additional treatment side effects and side effects based on prior 21 
or no prior experience of treatment separately. When studies that measured side effects in 22 
patients with and without previous treatment exposure were analysed together (See Table 1), 23 
the largest effect sizes were reported for anticipatory nausea and problems with 24 
16 
 
concentration, although the conclusiveness of the latter is mitigated by the fact that only two 1 
studies were included. Nonetheless, future research in the area of anticipated cognitive 2 
impairment following cancer treatment is required, particularly given the rising report of this 3 
form of potential impact from treatment in both the scientific (e.g., Janelsins et al. 
49
) and 4 
non-scientific media (e.g., the New York Times 
50
) including non-government cancer support 5 
organizations around the world (e.g., MacMillan in the UK 
51
, the Breast Cancer Network in 6 
Australia 
52
, and the Fred Hutchinson Center in the US 
53
). 7 
It is also interesting to note that although all side effects were positively associated 8 
with anticipation, post-treatment vomiting had the smallest effect size. Subsequent analysis 9 
separated studies where side effects were measured in patients who had not been previously 10 
exposed to treatment (see Table 2), from those where patients had previous treatment 11 
exposure (see Table 3). In the first case, the mechanism is hypothesised to involve response 12 
expectancies based upon information obtained directly or indirectly from expert or lay 13 
sources, whereas for the second conditioning could be at least part of the explanation. In both 14 
of these, post-treatment nausea remained the smallest effect, and was actually reduced to non-15 
significance in patients with no prior treatment experience after adjusting for publication bias. 16 
This result could reflect real or anticipated effects of any anti-emetics provided, an issue 17 
future research might address. 18 
We undertook a direct comparison between studies reporting data after a single 19 
treatment exposure (where the opportunity for classical conditioning of response was 20 
eliminated) with studies where side effect experience was measured after the patient had 21 
received multiple treatment cycles (where effects were likely a combination of expectations 22 
raised before treatment (i.e., cognitive expectancies) and reactions learned though experience 23 
(i.e., conditioned responses), as well as potential residual toxicity resulting from the 24 
cumulative effects of some treatments). The findings for anticipatory nausea confirmed 25 
17 
 
those of Sohl, Schnur and Montgomery 
6
. The experience of anticipatory nausea was more 1 
strongly related to anticipation among patients who had some previous treatment experience, 2 
in comparison to patients with no treatment experience, therefore highlighting a potential 3 
influence from classical conditioning. Contrary to the hypothesis, all other results (i.e., post-4 
treatment vomiting and fatigue), trended in the other direction. The one exception was post-5 
treatment nausea, where the effect size documenting the relationship between anticipation 6 
and side effects in patients with no prior treatment experience was r = 0.200 and r = 0.288 in 7 
patients with prior treatment experience. Although non-significant, this result suggests that 8 
further research might usefully consider the anticipated effectiveness of anti-emetic 9 
treatments. A small number of the studies included in the meta-analysis did control for the 10 
use of anti-emetic treatments or describe the relationship between anti-emetic use and 11 
subsequent nausea and vomiting 
10, 22, 23, 29-31, 34, 35
, however none specifically examined 12 
patients’ anticipation of the effectiveness of anti-emetic treatments.   13 
The implications of the findings for clinical practice should be considered. Several 14 
studies included in this review recommended providing patients with information prior to 15 
treatment in order to alter patient expectations. Although intervention studies provided some 16 
support for the use of acupressure bands for reducing nausea 
21
 and hypnosis for reducing 17 
post-surgery pain and distress 
16
, manipulations of the information given to patients did not 18 
result in changes in side-effects 
16
. Shelke et al. 
19
 found that providing information about the 19 
effectiveness of an antiemetic successfully altered patient expectations. However, pre-20 
intervention anticipation and not post-intervention anticipation was predictive of subsequent 21 
side effects. This suggests that simply changing patient education regarding side effects may 22 
not be effective in reducing expectancy effects. 23 
The data presented here are subject to significant limitations. The most significant of 24 
these is the inability to account for variance arising from an array of variables likely to impact 25 
18 
 
both the predictor variable, anticipated effect of treatment, and the outcome variable, report 1 
of side effects. For example, it is possible that variables like education, IQ, depression, 2 
anxiety, locus of control and optimism would all impact ratings of anticipation and the side 3 
effects experienced, and the extent to which these are positive or negative, irrespective of 4 
messages received about likely effects or any conditioning experienced. There is some 5 
support for this from an experimental study of pain expectancies, which found that pain 6 
expectancies played a mediating role between catastrophizing and depression and the actual 7 
pain experienced 
54
, although further research is required to test this. Furthermore, the nature 8 
and intensity of the chemotherapy regime and the medication provided to alleviate side 9 
effects are all potential confounds of reported side effects. There may also be a 10 
differentiated impact of the type of treatment on the side effects that patients 11 
experience. This was not examined in the present study due to the small number of 12 
studies that included participants undergoing treatment other than chemotherapy. 13 
More research is needed to examine the relationships between anticipation of side 14 
effects and actual experience of side effects in patients undergoing radiotherapy and 15 
surgery before meta-analysis can be conducted to provide meaningful insight. 16 
Our results confirm existing findings; anticipation of side effects positively predict the 17 
experience of these. In addition, our findings extend those of others by demonstrating their 18 
impact in a reasonably recent area of research in side effects of cancer treatment; cognition. 19 
Importantly, they highlight the potentially “additive” effects of conditioning following 20 
treatment on the impact made from expectations generated before any treatment, but only for 21 
anticipatory nausea. The failure to find an additive influence from treatment experience for 22 
other side effects suggests an important role for cognition in predicting treatment experience. 23 
19 
 
Future research could usefully explore patient reports of messages received about 1 
likely treatment effects both before and during treatment, and from whom these messages 2 
originate.  3 
In terms of conditioned responses, interview data could identify cues (i.e., the 4 
conditioned stimulus) that precede anticipatory nausea and vomiting in an attempt to develop 5 
strategies that could mitigate these associations. Further exploration of the anticipated 6 
outcomes attached to preventive therapies for side effects might also usefully identify 7 
strategies for minimisation of adverse treatment events. An increasing focus on the 8 
importance of measuring patient reported outcomes in cancer patients and survivors bodes 9 
well for increased concern about patient reported side effects and improved commitment 10 
from health providers to assist in their mitigation.   11 
20 
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Figure 1. Study flow diagram for systematic review.  
Identification 
11,339 records identified from electronic 
database searches 
2,868 duplicates removed Screening 
8,475 records (titles) screened against the 
inclusion/exclusion criteria 
8,250 records excluded 
225 records (abstracts) screened against the 
inclusion/exclusion criteria 
Eligibility 
107 full-text articles screened against the 
inclusion/exclusion criteria 
Included 
31 articles included in review 
118 records excluded 
76 full text articles excluded 
- Treatment expectations not measured (n = 47) 
- Literature review / Discussion paper (n = 13) 
- Didn’t investigate whether expectations were 
associated with side effect occurrence (n = 9) 
- Not specific to cancer patients (n = 3) 
- Palliative treatment (n = 1) 
- Complementary or alternative therapies  (n = 
1) 
- Focus on mental health issues (n = 1) 
- Not enough statistical information (n = 1) 
 
4 records identified through additional 
sources 
1,609 citations identified through update 
search. None met the eligibility criteria. 
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Table 1. Meta-analysis results for the relationships between expectations of side effects and actual experience of side effects in patients 
receiving treatment for cancer. 
Note: *p < 0.05, **p < 0.01, ***p < 0.001. 
k; number of studies; N, Number of participants; r, Pearson correlation coefficient; CI, Confidence Interval; I
2
, I
2
 statistic; Nfs, Fail-Safe N; %, 
Percentage.  
 
Side effect   Effect size 95% CI Rosenthal’s Orwin’s I2 
 k N r Lower Upper Nfs Nfs % 
Anticipatory nausea
 
5 359 0.442** 0.173 0.649 74 42 84.24*** 
Post-treatment nausea 25 4,054 0.230*** 0.161 0.297 827 53 75.520*** 
Post-treatment vomiting
 
11 1,166 0.181*** 0.123 0.238 91 30 0.00 
Fatigue 9 672 0.325*** 0.196 0.443 140 51 64.07** 
Pain 6 386 0.364*** 0.174 0.528 67 38 71.26** 
Problems with concentration
 
2 146 0.431*** 0.287 0.556 - - 0.00 
Skin reactions
 
4 858 0.290* 0.003 0.534 20 4 87.913*** 
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Table 2. Meta-analysis results for the relationships between expectations of side effects and actual experience of side effects in patients who had 
no previous treatment experience. 
Note: *p < 0.05, **p < 0.01, ***p < 0.001, 
a 
Only one study examined expectancies and experience of anticipatory nausea prior to any treatment, 
therefore there were not enough data to run the meta-analysis. 
b Egger’s test confirmed a publication bias, therefore adjusted effect size 
calculated using Duval and Tweedie’s trim-and-fill method. c Only two studies examined the relationship between response expectancies and 
problems with concentration, therefore publication bias analysis could not be conducted. Results should be interpreted with caution.  
k; number of studies; N, Number of participants; r, Pearson correlation coefficient; CI, Confidence Interval; I
2
, I
2
 statistic; Nfs, Fail-Safe N; %, 
Percentage.   
 
Side effect   Effect size 95% CI Rosenthal’s Orwin’s I2 
 k N r Lower Upper Nfs Nfs % 
Anticipatory nausea
a 
1 - 0.036 - - - - - 
Post-treatment nausea 17 3,553 0.200*** 0.121 0.277 372 30 78.726*** 
Post-treatment  vomiting 7 901 0.170*** 0.104 0.234 42 17 0.00 
Adjusted effect size
 b 
  0.153 0.092 0.213    
Fatigue 6 526 0.337*** 0.180 0.477 87 35 72.636** 
Pain 5 330 0.366** 0.141 0.554 50 32 76.975** 
Problems with concentration
c 
2 146 0.431*** 0.287 0.556 - - 0.00 
Skin reactions 3 802 0.278 -0.065 0.562 12 3 91.243*** 
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Table 3. Meta-analysis results for the relationships between expectations of side effects and actual experience of side effects in patients who had 
some previous treatment experience. 
Note: *p < 0.05, **p < 0.01, ***p < 0.001. 
a 
Only two studies examined the relationship between response expectancies and pain, therefore 
publication bias analysis could not be conducted. Results should be interpreted with caution. 
b 
None of the included studies examined the 
relationship between response expectancies and problems with concentration in patients with previous treatment experience. 
c
 Only one study 
examined expectancies and experience of skin reactions in patients with previous treatment experience, therefore there was not enough data to 
run the meta-analysis. 
k; number of studies; N, Number of participants; r, Pearson correlation coefficient; CI, Confidence Interval; I
2
, I
2
 statistic; Nfs, Fail-Safe N; %, 
Percentage.  
Side effect   Effect size 95% CI Rosenthal’s Orwin’s I2 
 k N r Lower Upper Nfs Nfs % 
Anticipatory nausea 5 359 0.476*** 0.237 0.660 90 46 81.44*** 
Post-treatment nausea 11 707 0.288*** 0.184 0.386 142 49 46.38* 
Post-treatment vomiting 5 390 0.211*** 0.096 0.320 13 17 12.99 
Fatigue 4 271 0.266** 0.090 0.427 11 18 36.20 
Pain
a 
2 86 0.235 -0.072 0.500 - - 32.31 
Problems with concentration
b 
0 - - - - - - - 
Skin reactions
c 
1 - - - - - - - 
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Table 4. Between groups analysis for the relationships between expectations of side effects and actual experience of side effects in patients with 
and without previous treatment experience 
 
 
 
 
 
 
 
 
 
 
Note: *p < 0.05, **p < 0.01, ***p < 0.001. 
a 
Only one study examined response expectancies and experience of anticipatory nausea in patients with no previous treatment experience (r = 
0.036 
12
), therefore result should be interpreted with caution.
 b 
None of the included studies examined response expectancies and experience of 
problems with concentration in patients with previous treatment experience. 
Side effect Heterogeneity 
 Q df p 
Anticipatory nausea
a 
6.353 1 0.012* 
Post-treatment nausea 1.817 1 0.178 
Post-treatment vomiting 0.772 1 0.380 
Fatigue 0.375 1 0.540 
Pain
 
0.516 1 0.472 
Problems with concentration
b 
- - - 
Skin reactions
 
0.079 1 0.778 
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Supplementary Table 1: Study characteristics 
Study n Side effect type Cancer type Treatment type Treatment experience Expectancies measured 
before treatment no. 
Side effect measured 
after treatment no. 
Andrykowski, 1988 
32
 
 
Qualsyst score: 0.82 
 
77 Anticipatory nausea Breast Chemotherapy No previous treatment 
experience 
First First and subsequent 
Andrykowski, 1992 
10
 
 
Qualsyst score: 0.89 
65 Post-treatment 
nausea 
Mixed Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at subsequent 
treatments 
First First and subsequent 
Booth, 2007 
28
 
 
Qualsyst score: 0.91 
143 Post-treatment 
vomiting 
Breast Chemotherapy Some previous treatment 
experience 
Multiple treatments Cessation of 
chemotherapy or 
maximum of 6 treatment 
cycles 
 
Cassileth, 1985 
24
 
 
Qualsyst score: 0.66 
56 Post-treatment 
nausea 
Post-treatment 
vomiting 
Fatigue 
Pain 
Skin reactions 
Mixed Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at second 
treatment 
First First and second 
(analyses conducted 
using side effects 
reported following 
second treatment)  
Cobeanu, 2013 
11
 
 
Qualsyst score: 0.69 
30 Post-treatment 
nausea 
Post-treatment 
vomiting 
Fatigue 
Pain 
Breast Chemotherapy Some previous treatment 
experience 
Treatment other than the 
first 
Treatment other than the 
first 
Colagiuri, 2008 
39
 
 
Qualsyst score: 0.82 
 
671 Post-treatment 
nausea 
Mixed Chemotherapy No previous treatment 
experience 
First First 
Colagiuri, 2013 
33
 
 
Qualsyst score: 0.75 
 
91 Post-treatment 
nausea 
Fatigue 
Mixed Chemotherapy No previous treatment 
experience 
First First 
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Study n Side effect type Cancer type Treatment type Treatment experience Expectancies measured 
before treatment no. 
Side effect measured 
after treatment no. 
Haut, 1991 
34
 
 
Qualsyst score: 0.84 
36 Post-treatment 
nausea 
Post-treatment 
vomiting 
Mixed Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at subsequent 
treatments 
First First and subsequent 
Hickok, 2001 
12
 
 
Qualsyst score: 0.80 
63 Anticipatory nausea 
Post-treatment 
nausea 
Mixed Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at third treatment  
First First and third 
Higgins, 2007 
22
 
 
Qualsyst score: 0.91 
 
56 Post-treatment 
nausea 
Breast Chemotherapy No previous treatment 
experience 
First First 
Jacobsen, 1988 
35
 
 
Qualsyst score: 0.83 
45 Post-treatment 
nausea 
Breast Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at subsequent 
treatments 
First First six treatments 
Molassiotis, 2002 
36
 
 
Qualsyst score: 0.95 
71 Post-treatment 
nausea 
Post-treatment 
vomiting 
Breast Chemotherapy No previous treatment 
experience 
First First 
Molassiotis, 2013 
31
 
 
Qualsyst score: 0.96 
 
286 Post-treatment 
nausea 
Post-treatment 
vomiting  
Mixed Chemotherapy No previous treatment 
experience 
First First, second, and third 
cycles 
Molassiotis, 2014 
29
 
 
Qualsyst score: 0.88 
Cycle 
1: 911 
Cycle 
2: 
888 
Cycle 
3: 769 
Post-treatment 
nausea 
Mixed Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at second and 
third treatments 
First First, second, and third 
cycles (data only for first 
cycle) 
Montgomery, 1998 
26
 
 
Qualsyst score: 0.88 
59 Anticipatory nausea Breast Chemotherapy No previous treatment 
experience 
First Sixth 
28 
 
Study n Side effect type Cancer type Treatment type Treatment experience Expectancies measured 
before treatment no. 
Side effect measured 
after treatment no. 
Montgomery, 2000 
25
 
 
Qualsyst score: 0.77 
52 Post-treatment 
nausea 
Breast Chemotherapy No previous treatment at 
first treatment 
 
Some previous treatment 
experience at subsequent 
treatments 
Multiple treatments Multiple treatments 
Montgomery, 2001 
13
 
 
Qualsyst score: 0.80 
 
60 Anticipatory nausea 
Fatigue 
Breast Chemotherapy Some previous treatment 
experience 
Third Third 
Montgomery, 2002 
16
 
 
Qualsyst score: 0.72 
 
20 Pain Breast Surgery No previous treatment 
experience 
Pre-surgery Post-surgery 
Montgomery, 2004 
14
 
 
Qualsyst score: 0.89 
 
63 Post-treatment 
nausea 
Fatigue 
Pain 
Breast Surgery No previous treatment 
experience 
Pre-surgery Post-surgery 
Montgomery, 2010 
15
 
 
Qualsyst score: 0.93 
 
101 Post-treatment 
nausea 
Fatigue 
Pain 
Breast Surgery No previous treatment 
experience 
Pre-surgery Post-surgery 
Olver, 2005 
37
 
 
Qualsyst score: 0.89 
87 Post-treatment 
nausea 
Post-treatment 
vomiting 
Fatigue 
Pain 
Skin reactions 
Problems with 
concentration 
Mixed Chemotherapy No previous treatment 
experience 
First First 
Rhodes, 1995 
27
 
 
Qualsyst score: 0.78 
329 Post-treatment 
nausea 
Post-treatment 
vomiting 
Not specified Chemotherapy No previous treatment 
experience 
First First 
Roscoe, 2000 (study 1) 
23
 
 
Qualsyst score: 0.77 
29 Post-treatment 
nausea 
Post-treatment 
vomiting 
Ovarian Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at second 
First First and second 
29 
 
Study n Side effect type Cancer type Treatment type Treatment experience Expectancies measured 
before treatment no. 
Side effect measured 
after treatment no. 
treatment 
Roscoe, 2000 (study 2) 
23
 
 
Qualsyst score: 0.77 
81 Post-treatment 
nausea 
Mixed Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at third treatment 
First First and third (data only 
for third treatment) 
Roscoe, 2004 
17
 
 
Qualsyst score: 0.73 
201 Post-treatment 
nausea 
Post-treatment 
vomiting 
Breast Chemotherapy No previous treatment 
experience 
First First 
Roscoe, 2009 
21
 
 
Qualsyst score: 0.72 
 
88 Post-treatment 
nausea 
Mixed Radiotherapy Some previous treatment 
experience 
Other than first Fifth treatment since 
study commencement  
Ryan, 2007 
18
 
 
Qualsyst score: 0.80 
 
656 Skin reactions Mixed Chemotherapy 
and/or radiation 
therapy 
No previous treatment 
experience 
First First 
Shelke, 2008 
19
 
 
Qualsyst score: 0.85 
 
358 Post-treatment 
nausea 
Mixed Chemotherapy No previous treatment 
experience 
First First 
Watson, 1998 
30
 
 
Qualsyst score: 1.0 
100 Anticipatory nausea 
Post-treatment 
nausea 
Breast Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at subsequent 
treatments 
First First and subsequent 
Whitford, 2012 
38
 
 
Qualsyst score: 0.82 
59 Post-treatment 
nausea 
Post-treatment 
vomiting 
Fatigue 
Pain 
Skin reactions 
Problems with 
concentration 
Mixed Chemotherapy No previous treatment 
experience 
First First 
30 
 
Study n Side effect type Cancer type Treatment type Treatment experience Expectancies measured 
before treatment no. 
Side effect measured 
after treatment no. 
Zachariae, 2007 
20
 
Zachariae, 2007 
48
 
 
Qualsyst score: 0.91 
125 Post-treatment 
nausea 
Post-treatment 
vomiting 
Fatigue 
Breast Chemotherapy No previous treatment 
experience at first treatment 
 
Some previous treatment 
experience at subsequent 
treatments 
First First, fourth, sixth, and 
last (seventh or ninth) 
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